Specification
Description
Tacedinaline, also known as CI-944 and PD123654, is a n orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations.
Synonyms
CI994, CI-994, CI 994, PD123654, PD-123654, PD 123654, Tacedinaline, acetyldinaline
IUPAC Name
4-acetamido-N-(2-aminophenyl)benzamide
Canonical SMILES
O=C(NC1=CC=CC=C1N)C2=CC=C(NC(C)=O)C=C2
InChI
InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
InChI Key
VAZAPHZUAVEOMC-UHFFFAOYSA-N
Solubility
Soluble in DMSO, not in water
Appearance
Off-white solid powder
Shelf Life
>5 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 66.90; H, 5.61; N, 15.60; O, 11.88
HS Tariff Code
2934.99.9001
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).